However, the use of CD133 marker is controversial as CD133– cells have also been shown to form tumors in glioma and CD133+ cells could be derived from CD133– cells in vivo, implying the underlying plasticity (Wang et al., 2008). The gene discussed is PROM1; the disease is central nervous system cancer.